Recent Quotes View Full List My Watchlist Create Watchlist Indicators DJI Nasdaq Composite SPX Gold Crude Oil EL&P Market Index Markets Stocks ETFs Tools Overview News Currencies International Treasuries Teva Pharmaceutical Industries ADR (NY: TEVA ) 17.49 UNCHANGED Streaming Delayed Price Updated: 7:00 PM EDT, Oct 4, 2024 Add to My Watchlist Quote Overview Detailed Quote Charting Historical Prices News All News News Headlines Press Releases Research Quarterly Reports Insider Filings Other Filings Price and Volume Detailed Quote Volume 1,554 Open 17.49 Bid (Size) 17.42 (5) Ask (Size) 17.44 (3) Prev. Close 17.49 Today's Range 17.49 - 17.49 52wk Range 8.055 - 19.08 Shares Outstanding 1,110,352,397 Dividend Yield N/A Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year Top News More News Medicare Drug Price Negotiation Program Gets Final Guidance For Second Cycle, $1.5B Savings Expected October 03, 2024 Guidance for the second cycle of Medicare drug price negotiations has expectations high for significant savings by 2026. Via Benzinga Teva and mAbxience Expand Strategic Partnership to include an additional Oncology Biosimilar Candidate October 03, 2024 From Teva Pharmaceutical Industries Ltd; mAbxience Via GlobeNewswire Performance YTD +63.92% +63.92% 1 Month -3.26% -3.26% 3 Month +6.91% +6.91% 6 Month +23.17% +23.17% 1 Year +98.30% +98.30% More News Read More Teva Launches Generic Version Of Sandostatin In The US October 01, 2024 Via Benzinga Teva Announces Launch of the First and Only Generic Version of Sandostatin® LAR Depot (octreotide acetate for injectable suspension), in the U.S. October 01, 2024 From Teva Pharmaceutical Industries Ltd Via GlobeNewswire If You Invested $1000 In This Stock 5 Years Ago, You Would Have $2,400 Today September 16, 2024 Via Benzinga Key Takeaways From Teva Pharmaceutical Indus Analyst Ratings September 03, 2024 Via Benzinga Teva to Host Conference Call to Discuss Third Quarter 2024 Financial Results at 8 a.m. ET on November 6, 2024 September 30, 2024 From Teva Pharmaceutical Industries Ltd Via GlobeNewswire $1000 Invested In Teva Pharmaceutical Indus 5 Years Ago Would Be Worth This Much Today September 30, 2024 Via Benzinga Corcept Therapeutics' Commercial Drug Korlym Sales Impress Despite Increased Competition, Analyst Boosts Price Forecast September 30, 2024 Via Benzinga As Fentanyl Crisis Escalates, Abuse-Deterrent Formulations to Zero in on the Rising Epidemic of Opiate Abuse September 24, 2024 Via FinancialNewsMedia Exposures Product Safety $1000 Invested In This Stock 5 Years Ago Would Be Worth $2,400 Today August 21, 2024 Via Benzinga As Fentanyl Crisis Escalates, Abuse-Deterrent Formulations to Zero in on the Rising Epidemic of Opiate Abuse September 24, 2024 From FN Media Group LLC Via GlobeNewswire Teva Announces Long Term Efficacy and Safety of Deutetrabenazine in European Patients with Debilitating Movement Disorder Tardive Dyskinesia September 23, 2024 From Teva Pharmaceutical Industries Ltd Via GlobeNewswire Teva Presents New Phase 3 Efficacy, Safety and Tolerability Data from SOLARIS Trial Evaluating TEV-‘749 (olanzapine) as a Once-Monthly Subcutaneous Long-Acting Injectable for Adult Patients Diagnosed with Schizophrenia September 21, 2024 From Teva Pharmaceutical Industries Ltd Via GlobeNewswire New Data Provide Treatment Insights into Options for Switching Adult Patients Diagnosed with Schizophrenia to UZEDY® (risperidone) Extended-Release Injectable Suspension from Perseris® (RBP-7000) September 21, 2024 From Teva Pharmaceutical Industries Ltd Via GlobeNewswire Teva to Present at the Bank of America 2024 Global Healthcare Conference September 11, 2024 From Teva Pharmaceutical Industries Ltd Via GlobeNewswire UnitedHealth Follows Competitors, Replaces Humira with Lower-Cost Biosimilars September 11, 2024 Via Benzinga Teva Announces $80M Settlement To Baltimore: City Continues Opioid Litigation Against Other Companies September 10, 2024 Via Benzinga JP Morgan Shows Most Interest In Teva, Organon As Specialty Pharma Sector Exhibits Signs Of Stability September 06, 2024 Via Benzinga Shortage Relief: More Takeda's Vyvanse For ADHD On the Way As US Ramps Up Production September 06, 2024 Via Benzinga Organon Stock Sees Relative Strength Rating Rise To 91 August 27, 2024 Via Investor's Business Daily Teva to Present at the Morgan Stanley 22nd Annual Global Healthcare Conference August 26, 2024 From Teva Pharmaceutical Industries Ltd Via GlobeNewswire Novo Nordisk's Ozempic Might Be Among 2027 Medicare Price Negotiation Targets August 23, 2024 Via Benzinga Organon Stock Earns Relative Strength Rating Upgrade; Hits Key Threshold August 20, 2024 Via Investor's Business Daily $100 Invested In Teva Pharmaceutical Indus 5 Years Ago Would Be Worth This Much Today August 13, 2024 Via Benzinga Data & News supplied by www.cloudquote.io Stock quotes supplied by Barchart Quotes delayed at least 20 minutes. By accessing this page, you agree to the following Privacy Policy and Terms and Conditions.
